Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Patients with Advanced Solid Tumors

類似資料

• Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
  著者:: Nayak-Kapoor, Asha, 等
  出版事項: (2018)
• Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
  著者:: Ebata, Takahiro, 等
  出版事項: (2019)
• Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
  著者:: Ma, Shuguang, 等
  出版事項: (2019)
• Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
  著者:: Spahn, Jessica, 等
  出版事項: (2015)
• Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
  著者:: Wang, Hanwen, 等
  出版事項: (2021)